Artificial Intelligence-Driven Discovery of Pyrazolo[1,5- a ]pyrimidine Derivatives as Novel Phosphodiesterase 4 Inhibitors for Treating Idiopathic Pulmonary Fibrosis

Authors:

Abstract
Phosphodiesterase 4 (PDE4) has been validated as a promising therapeutic target for idiopathic pulmonary fibrosis (IPF), a devastating interstitial lung disease lacking really effective therapeutic drugs, particularly exacerbated in the post-COVID-19 era. Herein, we reported the discovery of 13c, a novel pyrazolo[1,5-a]pyrimidine-based PDE4 inhibitor, via an innovative artificial intelligence (AI)-driven virtual screening approach integrated with structure-based design. The cocrystal analysis of PDE4-13c elucidated the structural basis of its high affinity, revealing that the unique "halogen-binding and metal-coordination" synergistic network significantly influenced PDE4 inhibitory activity, which resulted in a 268-fold potency enhancement (IC50 = 2.7 nM) over hit T3700 (IC50 = 725 nM). Notably, 13c exhibited remarkable hepatic microsomal stability (RLM1/2 = 141.4 min). Furthermore, 13c exhibited remarkable antifibrotic activity in vitro and significantly attenuated bleomycin-induced pulmonary fibrosis in vivo, highlighting its potential as a novel PDE4 inhibitor for IPF.
Funding Information
  • National Key Research and Development Program of China (2023YFF1205102)
  • Natural Science Foundation of Hainan Province (222RC556, 823CXTD375, 824RC500, 824YXQN420, KJRC2023B10)
  • Hainan University (KYQD(ZR)-21031, KYQD(ZR)-21108, KYQD(ZR)-21126, KYQD(ZR)23002, KYQD(ZR)-23003, XTCX2022JKA01)
  • National Natural Science Foundation of China (22277019, 22307031, 22367007, 22377023, 22567014, 82373732)
  • Excellent Talent Team Project in Hainan Province (HNYT20250004)

This publication has 48 references indexed in Scilit: